恶性脑肿瘤的下一代 CAR-T 治疗：2026 年 AACR 年会最新进展

Next-generation CAR-T therapy for malignant brain tumors: latest updates from the 2026 AACR Annual Meeting.

面向胶质母细胞瘤治疗的下一代 CAR-T 细胞工程改造：受体设计、抗原靶向与治疗持久性创新综述

Engineering next-generation CAR-T cells for glioblastoma treatment: a review of innovations in receptor design, antigen targeting, and therapeutic per

使用游离 DNA（cfDNA）和 RNA（cfRNA）在原发性与转移性 CNS 肿瘤的诊断和监测中

Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors.

这些发现表明，使用 CSF 的 DNA 和 RNA NGS 联合检测进行 LBx 是一种可靠的方法，可产生可能改变临床实践的信息。

胶质母细胞瘤的下一代治疗：挑战与未来方向

Next-generation therapeutics for glioblastoma: Challenges and future directions.

超分子免疫调节水凝胶剂以持久内源性免疫增强 CAR-T 疗法实现实体瘤清除

Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication.

PDPN 与 GD2 双靶向增强 CAR-T 细胞对胶质母细胞瘤的疗效并促进持久肿瘤控制

Dual targeting of PDPN and GD2 enhances CAR T cell efficacy against glioblastoma and promotes durable tumor control.

癌胎抗原作为嵌合抗原受体 (CAR)-T 细胞免疫治疗的新兴靶点：机遇与挑战

Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges.

H3 K27 变异型弥漫性中线胶质瘤时代的弥漫性内生性脑桥胶质瘤

Diffuse intrinsic pontine glioma in the era of H3 K27-altered diffuse midline glioma.

AI 驱动的放射组学和放射基因组学：支持胶质母细胞瘤细胞免疫治疗中假性进展的评估与鉴别

AI-driven radiomics and radiogenomics: supporting the assessment and differentiation of pseudoprogression in cellular immunotherapy for glioblastoma.

双效 CAR-T 细胞对胶质母细胞瘤肿瘤及微环境的靶向

Tumour and microenvironment targeting of glioblastoma with dual-acting CAR T cells.